论文部分内容阅读
目的探讨Fas、Fas L蛋白在肺癌组织中的表达及临床意义。方法应用免疫组化SP法检测89例原发性肺癌组织、12例淋巴结转移性肺癌组织、12例肺癌癌前病变组织和10例正常肺组织中Fas、Fas L蛋白表达情况。分析各指标间相关性及其与肺癌临床病理参数的关系。结果与对照组比较,Fas和Fas L在其他3组中表达差异显著(P<0.05)。Fas在肺癌细胞中主要分布于细胞质,而正常肺组织主要表达于细胞膜,Fas在非小细胞肺癌(NSCLC)中的阳性率高于小细胞肺癌(SCLC)(P<0.05),Fas L与肺癌的临床分期、淋巴结转移有关(P<0.05),Fas与Fas L呈负相关(P<0.05)。结论 Fas、Fas L蛋白的异常表达在肺癌的恶性发展中起重要作用,二者在肺癌的发生、发展、侵袭转移中起协同作用。
Objective To investigate the expression and clinical significance of Fas and Fas L protein in lung cancer. Methods The expressions of Fas and Fas L protein in 89 cases of primary lung cancer, 12 cases of lymph node metastatic lung cancer, 12 cases of precancerous lesions of lung and 10 cases of normal lung tissues were detected by immunohistochemical SP method. Analysis of the correlation between each index and its relationship with clinicopathological parameters of lung cancer. Results Compared with the control group, the expression of Fas and Fas L in the other three groups was significantly different (P <0.05). Fas was mainly distributed in the cytoplasm of lung cancer cells and normal lung tissues were mainly expressed in the cell membrane. The positive rate of Fas in non-small cell lung cancer (NSCLC) was higher than that in small cell lung cancer (SCLC) (P <0.05) (P <0.05). There was a negative correlation between Fas and Fas L (P <0.05). Conclusion The abnormal expression of Fas and Fas L proteins plays an important role in the malignant development of lung cancer. Both of them play a synergistic role in the occurrence, development, invasion and metastasis of lung cancer.